{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Monjazeb AM"],"funding":["NCATS NIH HHS","U.S. Department of Health & Human Services | NIH | National Cancer Institute","U.S. Department of Defense","NCI NIH HHS","NIAMS NIH HHS","NIH HHS"],"pagination":["5332"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10474145"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(1)"],"pubmed_abstract":["Stereotactic ablative radiotherapy (SABR) is a standard-of-care for medically-inoperable-early-stage non-small cell lung cancer (NSCLC). One third of patients progress and chemotherapy is rarely used in this population. We questioned if addition of the immune-checkpoint-inhibitor (ICI) atezolizumab to standard-of-care SABR can improve outcomes. We initiated a multi-institutional single-arm phase I study (NCT02599454) enrolling twenty patients with the primary endpoint of maximum tolerated dose (MTD); secondary endpoints of safety and efficacy; and exploratory mechanistic correlatives. Treatment is well tolerated and full dose atezolizumab (1200 mg) is the MTD. Efficacy signals include early responses (after 2 cycles of ICI, before initiation of SABR) in 17% of patients. Biomarkers of funct"],"journal":["Nature communications"],"pubmed_title":["Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial."],"pmcid":["PMC10474145"],"funding_grant_id":["W81XWH-15-2-0063","P30CA093373","NIH/NCI R01 CA240751","R00 CA256526","4R00CA256526","P30 CA093373","S10 OD032406","UL1 TR001863","K24 AR077313","R01 CA240751"],"pubmed_authors":["Merleev AA","Mirhadi A","Beckett L","Vick LV","Maverakis E","Murphy WJ","Morris LA","Luxardi G","Riess JW","Eastham D","Garcia L","Schalper KA","Li T","Monjazeb AM","Lara F","Shiao SL","Daly ME","Borowsky A","Canter RJ","Kelly K","Marusina AI","Chen S","McGee HM"],"additional_accession":[]},"is_claimable":false,"name":"Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial.","description":"Stereotactic ablative radiotherapy (SABR) is a standard-of-care for medically-inoperable-early-stage non-small cell lung cancer (NSCLC). One third of patients progress and chemotherapy is rarely used in this population. We questioned if addition of the immune-checkpoint-inhibitor (ICI) atezolizumab to standard-of-care SABR can improve outcomes. We initiated a multi-institutional single-arm phase I study (NCT02599454) enrolling twenty patients with the primary endpoint of maximum tolerated dose (MTD); secondary endpoints of safety and efficacy; and exploratory mechanistic correlatives. Treatment is well tolerated and full dose atezolizumab (1200 mg) is the MTD. Efficacy signals include early responses (after 2 cycles of ICI, before initiation of SABR) in 17% of patients. Biomarkers of funct","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Sep","modification":"2026-07-14T19:57:07.393Z","creation":"2025-02-19T01:18:01.146Z"},"accession":"S-EPMC10474145","cross_references":{"pubmed":["37658083"],"doi":["10.1038/s41467-023-40813-w"]}}